After the approval of mavacamten, a novel cardiac myosin inhibitor for symptomatic hypertrophic obstructive cardiomyopathy, a new medication in the same group is getting ready. Hypertrophic obstructive cardiomyopathy
Novel gene editing treatment with exa-cel has been recently approved for treatment of severe sickle cell disease and transfusion-dependent β-thalassemia [1]. It was six decades back that it
Hypertrophic cardiomyopathy, a disease with thickening of heart muscle, is an important cause of sudden cardiac death in athletes. But the 2024 Guidelines for Management of Hypertrophic Cardiomyopathy,
Holt-Oram Syndrome is a familial heart disease with skeletal malformations described by Mary Holt and Samuel Oram. Initial description was familial atrial septal defect associated with abnormalities of
It is well known that lipoprotein(a) is associated with increased risk of cardiovascular disease, including calcific aortic valve disease. New treatment modalities are being investigated in clincal trials
Stellate ganglion block is being increasingly used as a modality for treatment of drug refractory ventricular tachycardia. It is a simple bedside procedure which can very well be
Sudden cardiac death of athletes, though rare, is a shocking event for the family and often attract a lot of media attention. In the earlier era, once an
VICTORIA trial was a global study of vericiguat in subjects with heart failure with reduced ejection fraction. Vericiguat increases soluble guanylate cyclase activity and may help to improve
TIMELESS trial evaluated the role of thrombolysis with tenecteplase in patients with ischemic stroke due to large artery occlusion having favourable perfusion imaging, beyond 4.5 hours of symptom
GATEWAY trial (GAstric bypass to Treat obEse Patients With steAdy hYpertension) evaluated the effect of bariatric surgery in obese persons with hypertension [1]. 100 subjects were assigned to